<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">IJPharm</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0253-7613</issn>
      <issn pub-type="epub">1998-3751</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26997729</article-id>
      <article-id pub-id-type="pmc">4778214</article-id>
      <article-id pub-id-type="publisher-id">IJPharm-48-83</article-id>
      <article-id pub-id-type="doi">10.4103/0253-7613.174565</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Drug Watch</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Azithromycin induced bullous fixed drug eruption</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Das</surname>
            <given-names>Anupam</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sancheti</surname>
            <given-names>Karan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Podder</surname>
            <given-names>Indrashis</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Das</surname>
            <given-names>Nilay Kanti</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Dermatology, Medical College and Hospital, Kolkata, West Bengal, India</aff>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence to:</bold> Dr. Anupam Das, E-mail: <email xlink:href="anupamdasdr@gmail.com">anupamdasdr@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2016</year>
      </pub-date>
      <volume>48</volume>
      <issue>1</issue>
      <fpage>83</fpage>
      <lpage>85</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>07</day>
          <month>4</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>12</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Pharmacology</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Fixed drug eruption (FDE) is a common type of drug eruption seen in skin clinics. It is characterized by solitary or multiple, round to oval erythematous patches with dusky red centers, some of which may progress to bulla formation. Bullous FDE may be caused by a number of drugs. We hereby describe a case of azithromycin-induced bullous FDE; to the best of our knowledge, this is the first such case being reported.</p>
      </abstract>
      <kwd-group>
        <title>KEY WORDS</title>
        <kwd>Azithromycin</kwd>
        <kwd>bullous</kwd>
        <kwd>fixed drug eruption</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-1">
      <title>Introduction</title>
      <p>fixed drug eruption (FDE) characteristically recurs in the same site or sites each time the drug is administered; however, the number of involved sites may increase with each exposure. Acute lesions usually develop within 30 min to 8 h as sharply marginated, round to oval erythematous, and edematous plaques, which become dusky violaceous or brown and sometimes vesicular or bullous after re-administration of incriminating drug. Various morphological types of FDEs include morbilliform, scarlatiniform, erythema multiforme-like, Stevens&#x2013;Johnson syndrome-like, eczematous, urticaria, nodular, vesicular, bullous (may become toxic epidermal necrolysis-like in severe cases), nonpigmenting, and diffuse hypomelanosis.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] Diagnosis can be confirmed by provocation test (patch and/or oral). A hitherto unreported bullous FDE to azithromycin is being reported here.</p>
    </sec>
    <sec id="sec1-2">
      <title>Case Report</title>
      <p>A 35-year-old male presented to clinic with a bullous lesion over left ankle and erosions over genitalia. He had been prescribed azithromycin for Grade II acne vulgaris (tablet azithromycin 500 mg for three consecutive days a week for 4 weeks). The patient had taken a single tablet of azithromycin, the day before presenting to clinic. He developed burning sensation and itching in genitalia at midnight and multiple nonbullous lesions on lower leg and a single bulla over left ankle next morning. Patient was not receiving any concomitant drug. Patient had a history of similar lesions over the genitalia and left ankle in May 2014 following use of azithromycin for throat infection. This time, he developed additional lesions over the lower legs.</p>
      <p>Cutaneous examination revealed multiple 2&#x2013;4 mm erythematous patches over the legs [<xref ref-type="fig" rid="F1">Figure 1</xref>], erosive lesions over genitalia [<xref ref-type="fig" rid="F2">Figure 2</xref>], and a bullous lesion over left ankle [<xref ref-type="fig" rid="F3">Figure 3</xref>]. Patient was afebrile. Systemic examination did not reveal any abnormality. Patient did not give consent for skin biopsy. Routine blood parameters were found to be normal.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Multiple hyperpigmented patches over extensor aspect of lower limbs</p>
        </caption>
        <graphic xlink:href="IJPharm-48-83-g001"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Multiple erosions in genitalia suggestive of preexisting bulla</p>
        </caption>
        <graphic xlink:href="IJPharm-48-83-g002"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Bullous lesion over left ankle</p>
        </caption>
        <graphic xlink:href="IJPharm-48-83-g003"/>
      </fig>
      <p>A diagnosis of bullous FDE was made on the basis of clinical evidence. Oral provocation test and patch test with azithromycin were not performed. Azithromycin was stopped, and the patient was treated for FDE with oral prednisolone (30 mg/day for 5 days) and antihistaminics (levocetirizine 5 mg once daily for 7 days). On the first follow-up visit (after 7 days), the bulla was found to have ruptured leaving a pigmentation mark; the irritation over the lesions had decreased, and all the drugs were stopped. He was under periodic follow-up for treatment of the postinflammatory hyperpigmentation, but it was refractory to treatment. He has been counseled regarding the condition.</p>
      <p>Causality assessment by Naranjo score and WHO-Uppsala Monitoring Centre (UMC) scale categorized the reaction as &#x201C;probable&#x201D; (Naranjo's score = 6) adverse effect induced by azithromycin. Severity assessment using Modified Hartwig and Siegel ADR Severity Assessment Scale labeled the reaction as &#x201C;moderate&#x201D; (Level 3).</p>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>Discussion</title>
      <p>FDE is a specific cutaneous adverse reaction induced by an ever-expanding list of drugs. Bullous FDE has been reported with several drugs including phenylbutazone, acetaminophen, fluconazole, nimesulide, ciprofloxacin, and metronidazole.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>]</p>
      <p>Brocq first introduced the term FDE in 1894. Pathogenesis of FDE is complex. Interleukin (IL)-mediated survival of memory T cells is considered the most probable mechanism for development of FDE. CD8+ cells, liberating interferon-gamma, are found in large numbers in FDE lesions and IL-20 is thought to be responsible for site-specificity of lesions. Generally, lesions of FDE heal with residual pigmentation, thus being of cosmetic concern to patient. Treatment of FDE is symptomatic with systemic antihistamines and topical corticosteroids. Time interval between ingestion of offending drug and appearance of symptoms varies from 30 min to 8 h with a mean duration of about 2 h. In the present case, lesions developed 3 h following ingestion of suspect drug. Severe cases of generalized bullous FDE (GBFDE) warrant the attention and aggressive management of SJS or TEN.[<xref rid="ref2" ref-type="bibr">2</xref>] Furthermore, patients need to be counseled to avoid common offending drugs for FDE in future.</p>
      <p>Some workers suggest use of oral provocation tests and patch tests to confirm the diagnosis of FDE. However, evidence of efficacy of these tests is still lacking.[<xref rid="ref6" ref-type="bibr">6</xref>] Tests were not performed in the present case due to severity of the episode. Temporal association with azithromycin and previous history of a milder reaction with same drug at same sites, with residual hyperpigmentation, suggested the diagnosis of bullous FDE due to azithromycin. Azithromycin was labeled as &#x201C;probable&#x201D; cause of bullous FDE on the basis of Naranjo scale and WHO-UMC scale.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>] Besides, severity was graded as &#x201C;moderate&#x201D; based on the Modified Hartwig and Siegel ADR Severity Assessment Scale.[<xref rid="ref9" ref-type="bibr">9</xref>]</p>
      <p>Azithromycin is widely used and is generally considered a safe medicine. Acne vulgaris, an extremely common dermatosis, responds well to pulse azithromycin therapy, with an added advantage of better patient compliance.[<xref rid="ref10" ref-type="bibr">10</xref>] Gastrointestinal symptoms and reversible hearing loss are common. Potentially serious ADRs include angioedema and cholestatic jaundice in &gt;1% of patients. Azithromycin can cause severe skin reaction-fever, sore throat, swelling in face or tongue, burning in eyes, skin pain, followed by a red or purple skin rash that spreads, especially in the face or upper body and causing blistering and peeling.</p>
      <p>An extensive literature search on PubMed using the keywords &#x201C;azithromycin&#x201D; and &#x201C;bullous fixed drug rash&#x201D; did not reveal any results as on November 02, 2015. Inducing awareness among physicians about this hitherto unreported side effect of azithromycin is important since more such cases may be reported with extensive usage of the drug in future.</p>
      <sec id="sec2-1">
        <title/>
        <sec id="sec3-1">
          <title>Financial Support and Sponsorship</title>
          <p>Nil.</p>
        </sec>
        <sec id="sec3-2">
          <title>Conflicts of Interest</title>
          <p>There are no conflicts of interest.</p>
        </sec>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sehgal</surname>
              <given-names>VN</given-names>
            </name>
            <name>
              <surname>Srivastava</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Fixed drug eruption (FDE): Changing scenario of incriminating drugs</article-title>
          <source>Int J Dermatol</source>
          <year>2006</year>
          <volume>45</volume>
          <fpage>897</fpage>
          <lpage>908</lpage>
          <pub-id pub-id-type="pmid">16911371</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lipowicz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sekula</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ingen-Housz-Oro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Liss</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sassolas</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dunant</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognosis of generalized bullous fixed drug eruption: Comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis</article-title>
          <source>Br J Dermatol</source>
          <year>2013</year>
          <volume>168</volume>
          <fpage>726</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="pmid">23413807</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nath</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Adityan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Thappa</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Multifocal bullous fixed drug eruption due to fluconazole</article-title>
          <source>Indian J Dermatol</source>
          <year>2008</year>
          <volume>53</volume>
          <fpage>156</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">19882020</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumaran</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sandhu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Saikia</surname>
              <given-names>UN</given-names>
            </name>
            <name>
              <surname>Handa</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Nimesulide induced bullous fixed drug eruption of the labial mucosa</article-title>
          <source>Indian J Dermatol Venereol Leprol</source>
          <year>2004</year>
          <volume>70</volume>
          <fpage>44</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">17642560</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ada</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yilmaz</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Ciprofloxacin-induced generalized bullous fixed drug eruption</article-title>
          <source>Indian J Dermatol Venereol Leprol</source>
          <year>2008</year>
          <volume>74</volume>
          <fpage>511</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">19052425</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aberer</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Bircher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Blanca</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Campi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Drug provocation testing in the diagnosis of drug hypersensitivity reactions: General considerations</article-title>
          <source>Allergy</source>
          <year>2003</year>
          <volume>58</volume>
          <fpage>854</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">12911412</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naranjo</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Busto</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Sandor</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>EA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A method for estimating the probability of adverse drug reactions</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>1981</year>
          <volume>30</volume>
          <fpage>239</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="pmid">7249508</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="webpage">
          <article-title>The Use of the WHO-UMC System for Standardized Case Causality Assessment. World Health Organization (WHO) &#x2013; Uppsala Monitoring Centre</article-title>
          <date-in-citation>Last accessed on 2015 Sep 12</date-in-citation>
          <comment>Available from: <uri xlink:type="simple" xlink:href="http://www.who-umc.org/Graphics/24734.pdf">http://www.who-umc.org/Graphics/24734.pdf</uri></comment>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hartwig</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Siegel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Preventability and severity assessment in reporting adverse drug reactions</article-title>
          <source>Am J Hosp Pharm</source>
          <year>1992</year>
          <volume>49</volume>
          <fpage>2229</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="pmid">1524068</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singhi</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Ghiya</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Dhabhai</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>Comparison of oral azithromycin pulse with daily doxycycline in the treatment of acne vulgaris</article-title>
          <source>Indian J Dermatol Venereol Leprol</source>
          <year>2003</year>
          <volume>69</volume>
          <fpage>274</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">17642910</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
